PanTera

PanTera is a private joint venture between IBA (Ion Beam Applications) and SCK CEN, established to address the critical supply bottleneck for actinium-225, a key isotope for next-generation targeted alpha therapies. The company employs a unique, sustainable photonuclear ('gamma') production route using radium-226 to produce high-purity Ac-225. As a pure-play isotope supplier, PanTera operates in the pre-revenue stage, building its commercial-scale production capability to support the growing radiopharmaceutical pipeline of drug developers worldwide. Its success is pivotal for the scalability and accessibility of promising Ac-225-based cancer treatments.

Photonuclear ('gamma') production route for large-scale, sustainable manufacturing of high-purity actinium-225 (Ac-225) from a recycled radium-226 target.

Competition includes traditional small-scale suppliers (e.g., from U.S. DOE labs), other private companies exploring different production methods (e.g., linear accelerator-based), and large pharma developing internal supply. PanTera's joint venture with established nuclear and radiopharmaceutical players provides a unique competitive edge in credibility and expertise.